key: cord-0931738-4xjnl958
authors: Yadav, Pragya D; Sapkal, Gajanan N; Ella, Raches; Sahay, Rima R; Nyayanit, Dimpal A; Patil, Deepak Y; Deshpande, Gururaj; Shete, Anita M; Gupta, Nivedita; Mohan, V Krishna; Abraham, Priya; Panda, Samiran; Bhargava, Balram
title: Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin
date: 2021-07-06
journal: J Travel Med
DOI: 10.1093/jtm/taab104
sha: 4b3dcd9f5900852e38a2f54836d962c50c3dacc3
doc_id: 931738
cord_uid: 4xjnl958

SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-19 recovered cases and BBV152 vaccinees against Beta and Delta variants. BBV152 vaccine found to confer significant protection against both the variants.

Highlights SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-19 recovered cases and BBV152 vaccinees against Beta and Delta variants.

BBV152 vaccine found to confer significant protection against both the variants.

In the last several months, several SARS-CoV-2 variants have emerged from various countries worldwide. 1 Among them, variant of concern (VOC) i.e., Alpha (B. Here, we assessed the neutralization of sera from COVID-19 recovered cases (n=20)

post 5-20 weeks of infection and vaccinees 28 days after two doses of BBV152 (n=17)

against Beta, Delta variants and compared to prototype B.1 (D614G 

New SARS-CoV-2 variants-clinical, public health, and vaccine implications

Reduced sensitivity of infectious SARS-CoV-2 variant B. 1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Neutralization of B. 1.1. 28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of inactivated COVID-19 vaccine Covaxin